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The inhibition of  cerebral glutamine synthetase by structural analogs of  the 
convulsant dl-methionine sulfoximine 
(Received 5 October 1965; accepted 5 November 1965) 
GLUTAMINE synthetase [L-glutamate-ammonia ligase (ADP)] (EC 6.3.1.2) of rat cerebral cortex may 
be readily inhibited by the convulsant agent dl-methionine-di-sulfoximine (MSO), both in vitro and 
in vivo. 1, 8 Although in vitro this inhibition is readily reversible by excess substrate, L-glutamate, the 
inhibition in vivo appears to reflect a nonreversible interaction of the convulsant drug with the enzyme 
protein, which becomes maximal at the time the animal experiences the first seizure episode and which, 
as has been suggested, 8 possibly involves cunformatiunal changes in the enzyme molecule. As neither 
methionine sulfoxide nor methionine sulfone could be shown to inhibit in vivo the cerebral glutamine 
synthetase-glutamine transferas¢ system, 8 the examination of the contribution of the sulfoximino- 
moiety of MSO as a determining factor conferring specificity to the drug-enzyme interaction became 
of interest. 
In this communication we wish to report results of experiments in which four structural analogs of 
MSO, three S-alkyl-homocysteine sulfoximines, and one S-alkyl cysteine sulfoximine were evaluated 
as inhibitors of cerebral glutamine synthetase in vitro. 
M A T E R I A L S  A N D  M E T H O D S  
Rat cerebral cortex was homogenized in ice-cold distilled water.a, 4 and the homogenate (about 
1:10, w/v) was centrifuged at I1,000 rev/min in a Servall SS-34 superspeed centrifuge. The resulting 
sediment was resuspended in cold distilled water and r~r~ntrifuged as above and the supernatant 
added to that obtained after the first centrifugation. Sufficient 1 M NaC1 was then added to make the 
pooled supernatants 0-2 M in salt, and the solution was centrifuged at 17,000 rev/min for 1 hr. The 
resulting supernatant was used as the source of enzyme. Olutamine synthetase activity was routinely 
determined in a system containing in 3 mh K-glutamate, 20 mM; Tris-HCl buffer, pH 7.2, 80 mM;  
Mg 8+, 20 raM; freshly neutralized NH~OH-HCI, 50 mM;  ATP (Na sal0, 13-3 mM;  BAL, 0.5 mM;  
and suitable volumes of enzyme. After incubation (30 rain, 37 °) and enzyme inactivation, the assay 
was carried out as previously described, a In the control tubes, ATP was omitted. Inhibitor was added 
in water solution at concentrations indicated below. 
The f~lowing newly synthesized compounds were tested: S-ethyl-dl-homocysteine sulfoximine 
(ethionine sulfoximine, ESO), S-¢thyl-dl-cysteine sulfoximine (ECSO), S-n-propyl-dl-homocysteine 
sulfoximine (PSO), and S-n-butyl-d/-homocysteine sulfoximine (BSO).* 
R E S U L T S  
A. S-ethyl.dl-homoeysteine sulfoximine (ESO) 
S-methyl-dl-bomocysleine~-dl-sulfoximine, MSO, has been previously found to inhibit glutamine 
synthetase competitively with respect to one of its substrates, viz. L-glutamate} Thus, 5 x 10 --4 M 
MSO inhibits the enzyme 100, 80, and 40 per cent at concentrations of  L-glutamate of 4 × 10 -4 M, 
4 x 10 -3 M, and 4 x 10 -8 M respectively, As shown in Fig. 1, the lowest concentration of ESO 
effective as an inhibitor was 1 x 10 -a M, an inhibition of 20 per cent resulting at a concentration 
of L-glutamate of 1"6 x 10 -8 M. Raising [i] to 13 x 10 -8 M, while keeping IS] at 1.6 x 10 -8 M 
increased the inhibition to about 80 per cent. When [S] was increased to 10 × 10 -a M, inhibition was 
about 50 per cent at 13 x 10 -8 M inhibitor, i.e. with a ratio of substrate to inhibitor of approximately 
1. It could be calculated that for [S]: 10 x 10 -3 M, MSO at a concentration of about 1 x 10 -8 M 
was sufficient to inhibit the synthetase by about 50 per cent, indicating a more than 10-fold greater 
inhibitory capacity of  MSO as compared to ESO under these conditions. Plots of [I] (ESO) vs. 1/v 
* The synthesis, characterization, and study of the chromatographic behavior of the new sulfoxi- 
mines and of several sulfoxides of S-alkyl cysteines and homocysteines will be described elsewhere 
(O. Z. S¢llinger and Margaret A. Clarke). 
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at two substrate concentrations and of I/S vs. l /v  at [I]: 9 x 10 -a M gave evidence of competitive 
inhibition. A K~ value of 3.2 × 10 -a M was calculated. 
B. S-ethyl-dl-cysteine sulfoximine (ECSO) 
At equimolar concentrations and with L-glutamate at 10 × 10-a M, this analog of MSO was found 
to be equally effective as an inhibitor of glutamine synthetase as ESO (Table 1). However, while 
inhibition by ESO became proportionately more severe as the concentration of L-glutamate decreased 
or, conversely, that  of inhibitor increased (Fig. 1), inhibition by ECSO appeared to be less dependent 
on substrate concentration and failed to exceed a 50 per cent inhibition plateau. 
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FIG. I. The inhibition of cerebral glutamine syntbetase by S-ethyl-dl-homocysteine-dl-sulfoximine 
(ESO): the effect of  varying the concentration of suhstrate, L-glutamate. The per cent inhibition 
values were determined in vitro in an assay system, as described in the text. Inhibitor was added to the 
following final concentrations : l - - - - - 1 ,  1 x 10-aM;  [] 0 , 2  x 1 0 - a M ; H ,  4"8 x 10 -3 
M;  O O, 9 x 10 -3 M; • - • ,  13 x 10 -3 M;  and A A, 14 x 10 -a M. The dashed line 
represents the inhibition of glutamine syntbetase in the presence of 5 x 10 -4 M methionine 
sulfoximine. 
C. S-n-propyl-dl-homocysteine sulfoximine (PSO) 
This MSO analog was found to be less effective as a glutamine synthetase inhibitor than either 
ESO or ECSO (Table 1). This was particularly evident in the range of inhibitor concentrations between 
9 and 14 mM where approximately 50 per cent less inhibition was obtained as compared to ESO. 
D. S-n-butyl-dl-homocysteine sulfoximine (BSO) 
Lengthening the S-alkyl side chain from 3 to 4 carbons resulted in a further drop of the inhibitory 
power (Table 1). Thus, 2 mM BSO produced no inhibition, and 14 mM BSO was only half as effective 
as the same concentration of ESO. 
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TABLE I. INHIBITION OF CEREBRAL GLUTAMINE SYNTHETASE BY ANALOGS 
OF METHION1NE SULFOXIMINE* 
Concentration of MSO 
analog 
(mM) 
Inhibi t ion(~)  
ECSO ESOf PSO BSO 
2 21 17 14 0 
9 43 40 18 10 
14 48 55 32 25 
28 51 45 43 
* For comparison, 5 × 10 --4 M MSO (glutamate, 8 mM) inhibits 
68 per cent. 1 
Concentration of L-glutamate was 10 mM. The assay system, as 
described in Materials and Methods, was used. 
t Calculated from data in Fig. 1. 
D I S C U S S I O N  
The structural requirements for successful inhibition of cerebral glutamine syntbetase by substances 
competing with and resembling one of its substrates, viz. L-glutamate, have not been studied in 
detail. Braganca et al)  observed that MSO as well as methionine and ethionine sulfoxide may success- 
fully relieve the inhibition of synthesis of bound acetylcholine produced in a brain-slice system by the 
exogenous addition of ammonium ions. Other reports e- l l  have described an inhibitory action upon 
bacterial and sheep brain glutamine synthetase of methionine sulfoxide and of MSO, but only the 
latter molecule has been effective in inhibiting glutamine synthetase from rat cerebral cortex ~ both 
in vitro and in vivo. S-Benzyl homocysteine sulfoxide has also been reported to inhibit the growth of 
Lactobacillus arabinosus, an event which falls to take place in the presence of glutamine and which 
is reversed by increased levels of glutamate. TM Similar observations of Escherichia coli have been made 
with 3-amino-3-carboxypropanesulfonamide, the sulfonamide analog of glutamine. TM More recently, 
Mastalerz 14 has found y-phosphonoglutamate and P.ethyl-y-phosphonoglutamate to be strong 
inhibitors of glutamine synthetase. 
The present finding that the elongation of the S-alkyl side chain in the homocysteine sulfoximine 
series from CHs to n-butyl results in a gradual decline of the inhibitory power of the corresponding 
sulfoximine, indicates that substitution of the S atom and, to a lesser extent, the overall length of the 
inhibitor molecule are of importance as determinants of the enzyme-inhibitor interaction. Thus, in 
view of the equal inhibitory power of the S-ethyl-substituted sulfoximines, ECSO and ESO, a 5- and a 
5-carbon compound, respectively, it would appear that the length of the alkyl substituent on the 
S atom, rather than the total length of the molecule, determines the effectiveness of the drug-enzyme 
interaction in vitro. Insofar as the action in vivo of these MSO analogs as convulsants is concerned, 
the intraccrebral administration of ESO to rats has resulted in convulsions; however, the effective 
dose was about 100 times as large as that required with MSO. 
The data presented indicate that the structural analogs of MSO tested so far are considerably less 
effective as competitive inhibitors of cerebral glutamine syntbetase than is MSO itself. Strict structural 
requirements appear to exist for the competitive binding of the sulfoximines to the glutamine synthe- 
tase protein, one of which is the presence of the S-methyl group. The modalities governing this type 
of interaction, as well as the irreversible binding of MSO to glutamine synthetase which results in 
permanent activity loss, are at present under investigation. 
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Inhfoition of intestinal amino acid transport by dimethyl sulfoxide* 
(Received 11 October 1965; accepted 12 November 1965) 
TREATMENT of the malabsorptive state which is due to intestinal lesions is at present unsatisfactory. 
We have therefore begun a series of studies to evaluate the effect of agents that might increase the 
intestinal absorption of nutrients. One of the compounds tested, dimethyl sulfoxide (DMSO), had 
previously been utilized both as a vehicle for other compounds and as an anti-inflammatory agent 
because of its solvent and penetrant abilities. 1, 2 It has been noted that DMSO has a low order of 
systemic toxicity, but that it produces local toxic actions at high concentrations. 3 We wish to report 
that one of these undesirable effects, at high concentrations of DMSO, is inhibition of active amino 
acid transport. This raises doubts whether large quantities of DMSO could be used as a solvent to 
improve nutrient entry from the intestine in cases of malabsorption. 
Transport Of 1 × 10 -4 M L-alanine was followed by means of the generally labeled 14C compound 
(New England Nuclear Corp.). Everted intestinal sacs were prepared from adult hamsters of both 
sexes, which were allowed food and water ad libitum, 4 The initial condition was the same concentra- 
tion of L-alanine in both mucosal (5 ml) and serosal (1 ml) solutions. After gassing with 95 ~o O8 + 
5 ~o COs, flasks were stoppered and incubated for 1 hr at 37 °. Mucosal and scrosal fluids were 
drained, centrifuged to remove sloughed tissue, and then assayed for radioactivity. Transport was 
expressed in terms of micromoles L-alanine gained in the serosal fluid per unit wet weight of tissue. 
All values were compared with that of a control (three sacs from each of three hamsters, with Krebs- 
bicarbonate buffer, pH 7.4, as the solvent). Various volumes of DMSO were used to replace the buffer, 
to produce concentrations up to approximately 5 M. The pH of such solutions was adjusted to 7.4 
with a radiometer pH meter (although, because of nonaqueous DMSO effects, the actual pH may 
have been fractionally off this value; therefore, experiments were also run with the pH adjusted to 
0.3 unit above and 0.3 unit below this value). Experiments were additionally performed with the 
buffer plus DMSO in which salts were added to readjust their concentration to that found in the 
original Krebs-bicarbonate buffer. Results of the transport experiments in these cases were identical 
with those in which the salt content was not readjusted (and slight variations in pH had no effect). 
Transport of  L-alanine (nine sacs per experiment) was 52 4- 10 mpmoles/1.0 g sac (mean 4- S.D.) in 
the controls. There was no significant interference with transport at DMSO concentrations below 
0.3 M. 
